SCHEMBL1733468

SCHEMBL1733468

CCN(CCO)c1nc(C(N)=O)cc(-c2ccccc2OC)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.57
ADORA1 P30542 5/20 0.45
ADORA3 P0DMS8 4/20 0.45
ADORA2A P29274 3/20 0.44
ALDH1A1 P00352 4/20 0.42
HPGD P15428 4/20 0.42
HSD17B10 Q99714 3/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
ALOX15 P16050 1/20 0.41
CRHR1 P34998 1/20 0.40
HSP90AA1 P07900 2/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
HIF1A Q16665 1/20 0.39
HSP90AB1 P08238 1/20 0.39
IKBKB O14920 1/20 0.38
ABL1 P00519 1/20 0.38
PARP1 P09874 1/20 0.38
CHRNA7 P36544 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734495 0.95 KDM4E (0.51) KDM4EADORA1ADORA3ADORA2AALDH1A1
SCHEMBL1734511 0.92 KDM4E (0.66) KDM4EADORA1ADORA3ADORA2AALDH1A1
SCHEMBL1734477 0.82 KDM4E (0.65) KDM4EADORA1ADORA3ADORA2AALDH1A1
SCHEMBL1733611 0.82 KDM4E (0.83) KDM4EADORA1ADORA3ADORA2AALDH1A1
SCHEMBL1733692 0.82 ADORA3 (0.49) KDM4EADORA1ADORA3ADORA2AALDH1A1
SCHEMBL1734497 0.81 KDM4E (0.47) KDM4EADORA1ADORA3ADORA2ACRHR1
SCHEMBL1733458 0.81 KDM4E (0.56) KDM4EADORA1ADORA3
SCHEMBL1733739 0.81 KDM4E (0.65) KDM4EALDH1A1HPGDMAPTABL1
SCHEMBL1734572 0.80 KDM4E (0.61) KDM4EADORA1ADORA3ADORA2AALDH1A1
SCHEMBL1734279 0.80 KDM4E (0.64) KDM4EADORA1ADORA3ADORA2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US claimed
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 KDM4E 3910/4885ADORA1 142/4885ADORA3 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.